[Elsevier] OA-44 Pomalidomide, bortezomib, and dexamethasone vs bortezomib and dexamethasone in relapsed or refractory multiple myeloma (OPTIMISMM): final survival outcomes from a randomized, open-label, phase 3 trial

AsgerSand Post time 3 day(s) ago | Show all posts |Read mode
Reward10points

1.        Beksac M, Richardson P, Oriol A, et al. OA-44 Pomalidomide, bortezomib, and dexamethasone vs bortezomib and dexamethasone in relapsed or refractory multiple myeloma (OPTIMISMM): final survival outcomes from a randomized, open-label, phase 3 trial. Clinical Lymphoma Myeloma and Leukemia 2023; 23: S27-S8.

https://www.clinical-lymphoma-my ... /article/S2152-2650(23)01611-7/abstract

https://doi.org/10.1016/S2152-2650(23)01611-7
Reply

Use magic Donate Report

All Reply1 Show all posts
Mahmoud_Ebada Post time The day before yesterday 16:15 | Show all posts

Waiting for confirmation

If the PDF has not been accepted after 72 hours, the system will automatically adopt it.
Reply

Use magic Donate Report

Junior Member
  • post

  • reply

  • points

    20

Latest Reply

Return to the list